moneyheap
GSK · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK) stock moving?
GSK's Q3 2026 report (Oct 28) showed total sales of £8.9B (+5% at constant exchange rates), with Specialty Medicines up 15% to £3.9B and Core EPS up 1% to 54.6p. Total EPS fell 21% because of £328M in restructuring charges tied to the Accelerate Growth programme, and the 2026 outlook was reaffirmed. The shares fell 4.3% to a $48.74 close that day on about 8.1M shares, roughly double the 30-day average of about 4.1M. Since then the stock has recovered to $51.23 on Nov 10, about 5% above that close and slightly above the pre-results $50.94 level. Volume has been lighter in recent sessions, with the Nov 10 session at about 2.6M shares. Analyst views are split: Jefferies cut to Hold with a 2100 pence target and reportedly flagged pipeline concerns, while AlphaValue/Baader upgraded to Buy, Berenberg kept Buy at 2200 pence and Bernstein kept Outperform at 3004 pence. Other news is mostly routine: the 2027 provisional dividend calendar, the Alamar proteomics partnership, linerixibat data slated for AASLD, and R&D strategy comments that point to pivotal trials next year. Benzinga cites a 3.65% dividend yield, which supports the income case. No single item in this set is clearly transformative, and the Nov 4 rally on 5.3M shares had no clear catalyst in the news.
News behind the analysis
- GSK's Specialty Drugs Grow by Double Digits While Vaccines Slip in a Q3 BeatGSK beat Q3 consensus with $1.47 adjusted EPS and $11.95B revenue, as specialty drugs offset vaccine declines. The 2026 outlook was reaffirmed.
- Jefferies Downgrades GSK to Hold, Lowers Price Target to $55.9Jefferies cut GSK to Hold and lowered its price target to 2100 pence, citing concerns about the drug development pipeline and recent quarterly performance.
- AlphaValue/Baader Europe Upgrades GSK to BuyAlphaValue/Baader Europe upgraded GSK to Buy, offsetting Jefferies' downgrade in the same week of rating changes.
- Bernstein Research Adjusts GSK Price TargetBernstein lowered its GSK price target from 3010 to 3004 pence while keeping an Outperform rating.
- Alfasigma Announces GSK Presentations on Linerixibat at AASLD The Liver Meeting 2026GSK will present five studies on linerixibat for primary biliary cholangitis at the upcoming AASLD The Liver Meeting 2026.
- Berenberg Maintains 'Buy' Rating on GSKBerenberg reaffirmed its Buy rating and 2200 pence price target after GSK's third-quarter results.
- Alamar Biosciences Partners With GSK For Its Use Of NULISA Platform In Trial To Evaluate Protein SignaturesGSK partnered with Alamar Biosciences to use the NULISA platform in a large-scale study of protein signatures across respiratory, liver, kidney, neurological and autoimmune conditions.
- GSK publishes provisional dividend dates for 2027GSK released indicative 2027 dates, including Q1 results on Apr 28, 2027 and an ADS ex-dividend date of May 14, 2027. The dates may change.
- GSK Outlines R&D Strategy at Guggenheim Healthcare Innovation ConferenceGSK described its R&D priorities, focusing on human-validated targets and biomarker-led clinical trials for inflammatory diseases.
- Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend YieldsBenzinga lists GSK among healthcare stocks with high dividend yields, citing a 3.65% yield alongside recent analyst ratings.
About GSK plc American Depositary Shares (Each representing two Ordinary Shares)
GSK plc is a UK-based global biopharma company that makes prescription medicines and vaccines; the US-listed shares are ADRs, each representing two London-listed ordinary shares. It is one of the world's largest vaccine makers (including the shingles vaccine Shingrix) and runs a major HIV business through ViiV Healthcare, having spun off its consumer-health arm (Haleon) in 2022.
How it makes money
GSK sells medicines and vaccines to health systems, insurers and governments around the world. It reported revenue of about £24.9 billion for the first nine months of 2026. Using the Q1 2026 split as a rough guide, about 40%+ comes from Specialty Medicines, mainly HIV (around a quarter of total sales), respiratory/immunology and oncology. About 28% comes from Vaccines, with Shingrix the biggest product, followed by meningitis and RSV vaccines. Around 30% comes from General Medicines, such as the inhaler Trelegy. It reports in pounds sterling and pays a quarterly dividend (17p per share for Q3 2026).
What usually moves GSK
- Late-stage pipeline and trial results
- Sales of Shingrix and its HIV drugs
- Patent expiries and generic competition
- US drug pricing policy and litigation
- GBP/USD exchange rate